TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22815050
Drug: EV-077 1.875
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV-077 1.875 mg/kg
Study: 22815050
Drug: EV-077 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV-077 2.5 mg/kg
Study: 22815050
Drug: EV-077 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV-077 (all doses)
Study: 22815050
Drug: EV-077 (plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV-077 (plasma concentrations above 20 ng/ml)
Study: 17103040
Drug: Metronidazole (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (800 mg TID)
Study: 17103040
Drug: Satranidazole (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Satranidazole (300 mg TID with placebo at mealtime)
Study: 8267110
Drug: Clozapine with
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine with fluoxetine (N = 6)
Study: 29275118
Drug: Rituximab maintenance
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab maintenance (500 mg/m2 every 8 weeks for up to 2 years)
Study: 20810979
Drug: Higher dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dairy calcium intake (median for tertiles: 156.5, 358.0, and 582.9 mg/d)
Study: 20810979
Drug: Increased serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased serum 25(OH)D (14.5, 21.2, and 30.2 ng/mL for tertiles)
Study: 16683415
Drug: Curative radiation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Curative radiation therapy
Study: 16683415
Drug: Hypofractionated stereotactic
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated stereotactic body radiation therapy
Study: 14688709
Drug: No initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: No initial resection after neoadjuvant therapy for N2 nodal disease
Study: 12097595
Drug: HPV virus-like
Normalized name: chikungunya virus antigen, recombinant Senegal strain 37997
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV virus-like particle (VLP) vaccine administered intramuscularly at months 0, 2, 6, and a fourth dose at month 12 for half of the participants
Study: 12097595
Drug: HPV virus-like
Normalized name: chikungunya virus antigen, recombinant Senegal strain 37997
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV virus-like particle (VLP) vaccine
Study: 9814730
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 800 microg once daily
Study: 9814730
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 400 microg twice daily
Study: 27637737
Drug: Overdentures supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overdentures supported and retained by cantilevered bars on two canine implants (Group I)
Study: 27637737
Drug: Overdentures retained
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Overdentures retained by straight bars on two canine implants and supported by two-first molar implants (Group II)
Study: 24284154
Drug: Preoperative Radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative Radiation Therapy (RT)
Study: 24284154
Drug: Postoperative Radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative Radiation Therapy (RT)
Study: 24284154
Drug: No Radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Radiation Therapy (RT)
Study: 11358648
Drug: Estradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol valerate (2 mg/day)
Study: 11358648
Drug: Estradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol valerate (2 mg/day) + Dienogest (2 mg/day)
Study: 9000164
Drug: 0.45% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45% saline oral ingestion (ORAL)
Study: 9000164
Drug: 0.45% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45% saline infusion (i.v.)
Study: 31343548
Drug: Beetroot Juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot Juice (BEET) 400-mg nitrate
Study: 31343548
Drug: Citrulline Malate
Normalized name: CITRULLINE MALATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrulline Malate (CitMal) 8 g
Study: 27853809
Drug: Ciraparantag (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciraparantag (100 to 300 mg IV)
Study: 23553596
Drug: deferasirox 5
Normalized name: deferasirox 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: deferasirox 5 mg/kg/day
Study: 23553596
Drug: deferasirox 10
Normalized name: Deferasirox 100 mg dispersible oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: deferasirox 10 mg/kg/day
Study: 23553596
Drug: deferasirox 20
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: deferasirox 20 mg/kg/day (dose-escalated from 10 mg/kg/day at Week 24)
Study: 23553596
Drug: deferasirox >12.5-≤17.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: deferasirox >12.5-≤17.5 mg/kg/day
Study: 23553596
Drug: deferasirox dosing
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: deferasirox dosing strategies
Study: 21464362
Drug: CALM (cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: CALM (cognitive behavior therapy and pharmacotherapy recommendations)
Study: 16688562
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose Memory Training Control group (n=16)
Study: 11769634
Drug: Sibutramine 10
Normalized name: sibutramine 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 10 mg once a day
Study: 9263380
Drug: Sirolimus 3
Normalized name: temsirolimus 30 mg/3 mL (10 mg/mL) (first dilution) INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus 3 mg/m2
Study: 9263380
Drug: Sirolimus 5
Normalized name: SIROLIMUS 5 mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION [FYARRO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus 5 mg/m2
Study: 9263380
Drug: Sirolimus 10
Normalized name: sirolimus 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus 10 mg/m2
Study: 9263380
Drug: Sirolimus 15
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus 15 mg/m2
Study: 8513962
Drug: Low-dose cyclic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclic oral contraceptive (n = 28)
Study: 3799579
Drug: Prednisone alone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone alone (Treatment A)
Study: 3799579
Drug: Prednisone with
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone with sucralfate (Treatment B)
Study: 3799579
Drug: Prednisone with
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone with sucralfate administered 2 h after (Treatment C)
Study: 24163147
Drug: Decision Aid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decision Aid (DA) for dabigatran vs warfarin
Study: 20883736
Drug: PCV7+MnCC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV7+MnCC vaccine
Study: 17690599
Drug: Paliperidone extended-release
Normalized name: Paliperidone Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone extended-release 9 mg/day
Study: 11851743
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BTX‐A) injections
Study: 11851734
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no BTX‐A injections)
Study: 9745864
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (rhGH) 30 U/m2 per week
Study: 7803226
Drug: Hypnotic suggestions
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic suggestions to increase cutaneous blood flow
Study: 7803226
Drug: Hypnotic suggestions
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic suggestions to decrease cutaneous blood flow
Study: 30200394
Drug: ORS⁺Lr&amp;Z (Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORS⁺Lr&amp;Z (Oral Rehydration Solution enriched with Lactobacillus reuteri DSM 17938 and zinc)
Study: 27232649
Drug: Oral betrixaban
Normalized name: Betrixaban
DrugBank: Betrixaban (DB12364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral betrixaban (80 mg once daily for 35 to 42 days)
Study: 27232649
Drug: Subcutaneous enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous enoxaparin (40 mg once daily for 10±4 days)
Study: 25306266
Drug: Conventional yogurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional yogurt (300 g/d)
Study: 22574586
Drug: Mesalazine enteric
Normalized name: mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalazine enteric coated tablet (MSRT, 1.0 g, 4 times daily) in the active stage, MSRT (0.5 g, three times daily) in the remission stage
Study: 19443680
Drug: Telavancin 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telavancin 10 mg/kg
Study: 12623762
Drug: Troleandomycin (TAO)
Normalized name: TAO brand of troleandomycin
DrugBank: Troleandomycin (DB13179)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Troleandomycin (TAO) 500 mg daily for 2 days before omeprazole (OP) administration
Study: 1650685
Drug: Transcatheter hepatic
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter hepatic arterial chemo-embolizations with MMC 20 mg
Study: 1650685
Drug: Transcatheter hepatic
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter hepatic arterial chemo-embolizations with MMC 20 mg plus lipiodol 10 ml
Study: 1650685
Drug: Transcatheter hepatic
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter hepatic arterial chemo-embolizations with MMC 20 mg plus MTXmc 150 mg
Study: 1650685
Drug: Direct puncture
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct puncture of the main trunk of the portal vein to infuse 500 mg of 5-FU during operation
Study: 1650685
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of MMC 20 mg through a catheter inserted into the hepatic artery 4 weeks after operation
Study: 6131800
Drug: Naftidrofuryl (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftidrofuryl (40 mg in 5 ml i.m. three times daily for 6 days)
Study: 6131800
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 ml in normal saline i.m. three times daily for 6 days)
Study: 31476429
Drug: Alprazolam (GABAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (GABAA agonist)
Study: 31476429
Drug: Baclofen (GABAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (GABAB agonist)
Study: 26013322
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (hypertonic saline with lidocaine)
Study: 26013322
Drug: Open treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open treatment (hypertonic saline with lidocaine)
Study: 26013322
Drug: Hidden treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hidden treatment (hypertonic saline with lidocaine)
Study: 24755125
Drug: Tamsulosin hydrochloride
Normalized name: Tamsulosin Hydrochloride
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamsulosin hydrochloride modified release capsules (0.4 mg) alone and with mirabegron (100 mg once daily)
Study: 24755125
Drug: Co-treatment of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-treatment of mirabegron and tamsulosin
Study: 18086052
Drug: Calcium hydroxylapatite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium hydroxylapatite (CaHA) gel
Study: 2147702
Drug: Outpatient group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient group behavioral therapy including aerobic exercise (BE)
Study: 2147702
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy only (B)
Study: 2147702
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (BE, B, E)
Study: 6986967
Drug: Oral mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral mercaptopurine and methotrexate for 18 months (for all children)
Study: 31628035
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist luteal support (0.1 mg subcutaneously every other day, starting on day 3 after embryo transfer)
Study: 31628035
Drug: HCG luteal
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCG luteal support (80 µg on day 3 after embryo transfer)
Study: 20237169
Drug: Pioglitazone (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (45 mg)
Study: 18540369
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with methylprednisolone (mPSL) and high-dose immunoglobulin (IVIg)
Study: 18540369
Drug: Non-combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-combination therapy (IVIg alone)
Study: 14607447
Drug: Short-term dobutamine
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term dobutamine infusion (10 microg/kg/min) in CHF patients
Study: 14607447
Drug: 48-hour dobutamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48-hour dobutamine infusion (10 microg/kg/min) in CHF patients
Study: 14607447
Drug: Short-term dobutamine
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term dobutamine infusion (10 microg/kg/min) in matched controls
Study: 14607447
Drug: Short-term dobutamine
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term dobutamine infusion (10 microg/kg/min) in young controls
Study: 9161192
Drug: Oral injection
Normalized name: Iohexol 300 mg in 1 mL ORAL INJECTION, SOLUTION [OMNIPAQUE]
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral injection
Study: 1616866
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment with LHRH analogue followed by deferred orchidectomy
Study: 3908283
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg t.i.d.) plus dipyridamole (75 mg t.i.d.)
Study: 29357482
Drug: Acetaminophen (APAP)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (APAP) 1,000 mg/6 h for 24 h before resistance exercise
Study: 11041320
Drug: Hydrocortisone, 20
Normalized name: Hydrocortisone, 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone, 20 mg twice daily
Study: 9048274
Drug: Ophthalmic timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic timolol (50 microL of 0.5%)
Study: 8312212
Drug: Single insertion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single insertion of vaginal tablets of prostaglandin E2 (PGE2) containing 3mg of dinoprostin
Study: 8312212
Drug: Single insertion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single insertion of vaginal tablets of prostaglandin E2 (PGE2)
Study: 2655681
Drug: Frusemide 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide 10 mg
Study: 3518770
Drug: Frusemide 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide 20 mg
Study: 24529502
Drug: Clopidogrel therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel therapy (75mg/day)
Study: 22133776
Drug: Thalidomide 400
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide 400 mg/day
Study: 19682274
Drug: 8% lidocaine
Normalized name: LIDOCAINE 18 g in 100 g TOPICAL CREAM [Tattoo Numbing Cream 18% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% lidocaine pump spray (XPS)
Study: 19682274
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo pump spray (PPS)
Study: 17227903
Drug: Increased cytotoxic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased cytotoxic dose intensity through conventional means (support of hematopoietic growth factors, shortening treatment intervals)
Study: 17227903
Drug: Megadose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Megadose chemotherapy with the support of autologous bone marrow transplantation
Study: 15096921
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Botox + Zyderm II collagen)
Study: 12235445
Drug: Peppermint oil
Normalized name: Peppermint Oil
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peppermint oil (600 mg)
Study: 12235445
Drug: Ascorbyl palmitate
Normalized name: Ascorbyl Palmitate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascorbyl palmitate (500 mg)
Study: 7989386
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (40 mg of enoxaparin the evening before the operation and once a day subsequently)
Study: 7989386
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (5000 international units the evening before the operation and three times a day thereafter)
Study: 2648897
Drug: Oral transmucosal
Normalized name: Thrive, 2 mg oral transmucosal gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmucosal fentanyl citrate (OTFC) 15‐20 micrograms/kg
Study: 2648897
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution (meperidine 1.5 mg/kg, diazepam 0.2 mg/kg, atropine 0.02 mg/kg) 0.25 ml/kg
Study: 31685472
Drug: CRS3123 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRS3123 200 mg
Study: 31685472
Drug: CRS3123 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRS3123 400 mg
Study: 31685472
Drug: CRS3123 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRS3123 600 mg
Study: 31685472
Drug: CRS3123 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRS3123 (all doses)
Study: 31685472
Drug: CRS3123 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRS3123 200 mg and 400 mg
Study: 23500251
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg prasugrel loading dose
Study: 23500251
Drug: 180 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg ticagrelor loading dose
Study: 19018814
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied nightly for 6 weeks with occlusion
Study: 17298349
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate hydrofluoroalkane (FP-HFA) inhaled through the nose using a large volume spacer attached to a face mask
Study: 17298349
Drug: Nasal spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray of isotonic saline plus oral inhalation of FP-HFA through a mouthpiece attached to the same spacer
Study: 15229463
Drug: 5-fluorouracil (5FU)
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5FU) alone in standard de Gramont regimen (400 mg/m(2) bolus plus 600 mg/m(2) infusion)
Study: 15229463
Drug: 5-fluorouracil (5FU)
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5FU) plus oxaliplatin (85 mg/m(2)) in standard de Gramont regimen
Study: 15229463
Drug: 5-fluorouracil (5FU)
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5FU) alone in modified de Gramont regimen (400 mg/m(2) bolus plus 2400 mg/m(2) infusion)
Study: 15229463
Drug: 5-fluorouracil (5FU)
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5FU) plus oxaliplatin (85 mg/m(2)) in modified de Gramont regimen
Study: 11069821
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of ENO values in steroid-naive vs steroid-treated asthmatic children
Study: 3751735
Drug: Pentazocine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine (40 mg)
Study: 3751735
Drug: Pentazocine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine (80 mg)
Study: 3751735
Drug: Tripelennamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripelennamine (50 mg)
Study: 3751735
Drug: Tripelennamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripelennamine (100 mg)
Study: 3751735
Drug: Pentazocine and
Normalized name: pentazocine and naloxone
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentazocine and tripelennamine combination
Study: 23723326
Drug: N-terminal pro-B-type
Normalized name: N-terminal pro-B-type natriuretic peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) >400 ng/l
Study: 22950600
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (100 mg/day for 2 months)
Study: 19465537
Drug: Moderate-dose MPH
Normalized name: MPH
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate-dose MPH (0.6 mg/kg)
Study: 19465537
Drug: Low-dose MPH
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose MPH (0.3 mg/kg)